Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a unique subtype of non-small cell lung cancer (NSCLC) with a high degree of malignancy and poor therapeutic effects. With the widespread use of immune checkpoint inhibitors (ICIs) in recent years, few studies have reported that immunotherapy is e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shugui, Wu, Shanlian, Liao, Xiaohong, Zhou, Chaoming, Qiu, Feng, Wang, Chen, Zhong, Wenjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626500/
https://www.ncbi.nlm.nih.gov/pubmed/37936698
http://dx.doi.org/10.3389/fimmu.2023.1274937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626500/
https://www.ncbi.nlm.nih.gov/pubmed/37936698
http://dx.doi.org/10.3389/fimmu.2023.1274937

Ejemplares similares